In an exciting development, Amplia has appointed internationally renowned drug developer, José Iglesias M.D, as its Oncology Clinical Advisor.
Dr Iglesias has over 33 years’ experience in the pharmaceutical industry, having occupied international leadership positions and developed a wide range of anticancer drugs, from early to late phase clinical studies. He was responsible for the development of Abraxane® which is the cornerstone for the standard of care for pancreatic cancer, the first planned clinical indication for AMP945.
Dr Iglesias joins at a critical time for the Company. His extensive experience in the clinical development of new oncology drugs will be invaluable as Amplia advances to Phase 2 clinical trial of AMP945 in pancreatic cancer patients in 2022.
In Dr Iglesias’ words:
“I am very pleased to be working with Amplia on their exciting new approach to tackle pancreatic cancer. Pancreatic cancer continues to be such a devastating and poorly managed disease that new approaches to treatment, like the one being pursued by Amplia, are urgently required. I am really excited to join this great team of people at this stage of drug development.”
Read the ASX release.
